FineMark National Bank & Trust’s Teva Pharmaceuticals TEVA Stock Holding History

FineMark National Bank & Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,660	Closed	-$94K	–	1470
2015 Q3	$94K	Buy	1,660 +115	+7%	+$7.46K	0.01%	475
2015 Q2	$92K	Buy	1,545 +179	+13%	+$11K	0.01%	506
2015 Q1	$85K	Sell	1,366 -2,205	-62%	-$128K	0.01%	528
2014 Q4	$205K	Sell	3,571 -2,225	-38%	-$124K	0.03%	341
2014 Q3	$312K	Buy	5,796 +50	+0.9%	+$2.65K	0.05%	260
2014 Q2	$301K	Sell	5,746 -371	-6%	-$19K	0.05%	264
2014 Q1	$323K	Sell	6,117 -312	-5%	-$14.4K	0.06%	242
2013 Q4	$258K	Buy	6,429 +581	+10%	+$22.9K	0.05%	275
2013 Q3	$221K	Sell	5,848 -129	-2%	-$5.03K	0.05%	287
2013 Q2	$234K	Buy	+5,977	New	+$233K	0.07%	252

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

FineMark National Bank & Trust's TEVA Position: Q4 2015 in Review

FineMark National Bank & Trust sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 1,660 shares — an estimated $94K sold.

FineMark National Bank & Trust first reported a position in TEVA in Q2 2013 and held it in 10 quarters. The position peaked at $323K in Q1 2014. 877 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

FineMark National Bank & Trust reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
FineMark National Bank & Trust sold 1,660 Teva Pharmaceuticals shares in Q4 2015, an estimated $94K.
FineMark National Bank & Trust first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 10 quarters.
FineMark National Bank & Trust's Teva Pharmaceuticals position peaked at $323K in Q1 2014.
877 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on FineMark National Bank & Trust's 13F filing for Q4 2015, filed 9 Feb 2016.